A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis

Summary

Primary Objective: To assess the safety and tolerability of GZ402668 after a single subcutaneous (SC) dose in men and women with progressive multiple sclerosis. Secondary Objectives: To assess in men and women with progressive multiple sclerosis: * The pharmacokinetic (PK) parameters of GZ402668 after a single SC dose. * The pharmacodynamic (PD) response to GZ402668 after a single SC dose.

Timeline

Start

2016-12-01

Primary completion

2018-05-16

Completion

2018-05-16

Publications

• Albach FN, Geier C, Keicher C, Posch MG, Schreiber SJ, Grutz G, Akyuz L, Luo X, Le-Halpere A, Truffinet P, Wagner F. Phase 1 Trials of Gatralimab, a Next-Generation Humanized Anti-CD52 Monoclonal Antibody, in Participants with Progressive Multiple Sclerosis. Neurol Ther. 2024 Dec;13(6):1607-1625. doi: 10.1007/s40120-024-00659-w. Epub 2024 Sep 9.

Drugs

Indications